Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.
Pediatric patients receiving a donor stem cell transplant who have healthier pretransplant gut microbiota diversity show improved rates of survival and a lower risk of acute GvHD.
Adding quizartinib to standard induction chemotherapy significantly improves overall survival in patients with newly diagnosed acute myeloid leukemia regardless of prior stem cell transplantation.
Engraftment of Vertex Pharmaceutical s VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.